NASDAQ · Drug Manufacturers - Specialty & Generic

ESPR (ESPR) Stock

$3.18 +0.00% NASDAQ: ESPR Healthcare

Valuation

MetricValue
Price$3.18
Market Cap$661.15M
P/E Ratio-131.40
P/B Ratio-2.60
P/S Ratio1.58
EPS (TTM)$-0.11
52-Week High$4.18
52-Week Low$1.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE1.99%
ROA-1.60%
ROCE46.73%
Gross Margin14.89%
Operating Margin14.89%
Net Margin-1.77%
Debt/Equity-1.77
Current Ratio0.56

Annual Financials (USD)

Metric20212022202320242025
Revenue$78.0M$75.0M$116.0M$332.0M$403.0M
Operating Profit$-227.0M$-180.0M$-156.0M$54.0M$60.0M
Net Profit$-269.0M$-234.0M$-209.0M$-52.0M$-23.0M
EPS$-11.03$-4.33$-2.03$-0.28$-0.11
Op Margin-289.0%-237.8%-133.7%16.4%14.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$382.0M$248.0M$206.0M$344.0M$466.0M
Total Liabilities$579.0M$572.0M$661.0M$733.0M$768.0M
Cash$209.0M$125.0M$82.0M$145.0M$168.0M
Borrowings$260.0M$261.0M$541.0M$591.0M$548.0M

Latest News

Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger MarketBeat · Jul 10, 2026 Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades Simply Wall St. · Jun 23, 2026 Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report? Zacks · Jun 12, 2026 Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue? Zacks · Jun 10, 2026 Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-264.0M$-175.0M$-135.0M$-24.0M$-13.0M
Investing Cash Flow$-50.0M$8.0M$43.0M$-1.0M$0
Financing Cash Flow$50.0M$0$-6.0M$-40.0M$-7.0M
Net Cash Flow$-46.0M$-134.0M$-43.0M$63.0M$23.0M
Free Cash Flow$-264.0M$-175.0M$-135.0M$-24.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.40
EV / EBITDA26.29
FCF Yield-2.75%
Quick Ratio1.18
Interest Coverage1.67
Return 1Y169.49%
Return 3Y120.83%
Return 5Y-82.01%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGIOAgios Pharmaceuticals, Inc. $37.00 -0.51% -4.54 $2.21B 0.00%
COLLCollegium Pharmaceutical, Inc. $22.96 -2.30% 14.47 $747.48M 0.00%
EBSEmergent BioSolutions Inc. $6.23 +0.00% -1.84 $319.43M 0.00%
HRTXHeron Therapeutics, Inc. $0.30 +2.23% -1.86 $57.49M 0.00%
KPTIKaryopharm Therapeutics Inc. $0.52 -5.24% -0.02 $11.74M 0.00%

About ESPR

ESPR is led by CEO Sheldon L. Koenig, employs 304 people, headquartered in US, publicly traded since 2013.

ESPR stock trades at $3.18 with a market capitalization of $661.15M. The stock is valued at a negative price-to-earnings (P/E) ratio of -131.40, reflecting a net loss over the last twelve months, a negative price-to-book of -2.60, reflecting negative shareholders' equity, price-to-sales of 1.58. Over the past 52 weeks the stock has ranged between $1.10 and $4.18, and currently trades 23.9% below its 52-week high.

On profitability, ESPR generates a return on equity (ROE) of 1.99% (not meaningful, as shareholders' equity is negative), return on capital employed of 46.73%, an operating margin of 14.89%, a net profit margin of -1.77%.

ESPR by the numbers, 2016–2025

Between 2016 and 2025 ESPR reported revenue of $0 rising to $403.0M. Compounded, revenue has grown 12.1% a year over five years, 75.2% over three, 21.4% over the last twelve months. Net profit rose to $-23.0M.

The most recent net margin is -1.77%. On a trailing twelve-month basis to Mar '26, revenue is $417.0M and net profit $-7.0M.

Borrowings rose from $3.0M to $548.0M, cash from operations was $-13.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 55.1% over five years, and was 7.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

ESPR (ESPR) — frequently asked questions

What is ESPR (ESPR) stock price today?

ESPR (ESPR) is currently trading at $3.18, up 0% today.

What is ESPR P/E ratio?

ESPR's P/E ratio is -131.40. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is ESPR return on equity (ROE)?

ESPR's return on equity (ROE) is 1.99%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is ESPR's market cap?

ESPR has a market capitalization of $661.15M.

Does ESPR pay a dividend?

ESPR is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does ESPR carry?

ESPR has a debt-to-equity ratio of -1.77. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is ESPR's profit margin?

ESPR reports a net profit margin of -1.77% — the share of revenue left after every cost, including tax and interest.

What sector is ESPR in?

ESPR is classified under Healthcare, in the Drug Manufacturers - Specialty & Generic industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is ESPR listed on?

ESPR trades on NASDAQ under the ticker ESPR.

What is ESPR's 52-week range?

Over the last year ESPR has traded between $1.10 and $4.18.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens ESPR currently matches

On the figures above, ESPR passes the filters for 8 of our ready-made screens, among them Penny Stocks, Small Cap Stocks, Stocks Under $5. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Penny StocksSmall Cap StocksStocks Under $5Stocks Under $10High ROCE StocksStocks Under $100Stocks Under $50Negative Working Capital Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.